Prescribing propranolol for infantile hemangioma: Assessment of dosing errors
To the Editor: Infantile hemangiomas (IHs) affect 4% to 5% of infants. 1 A subset of high-risk IHs can have significant complications. In 2008, oral propranolol was discovered to be an effective treatment. 2 Generic propranolol hydrochloride oral solution (Roxane Laboratories by West-Ward Pharmaceuticals, Eatontown, NJ) is commercially available in 2 concentrations: 4 mg/mL and 8 mg/mL. It is widely used off-label to treat high-risk IH at 1 to 3 mg/kg/day in 2 to 3 divided doses.
In 2014, a unique oral pediatric formulation was approved by the US Food and Drug Administration (FDA), and established as first-line therapy for highrisk IH.
3 Hemangeol (Pierre Fabre Pharmaceuticals Inc, Parsippany, NJ) is available in a single concentration of 4.28 mg/mL including the molecular weight of propranolol hydrochloride, as required by the FDA. The recommended dose, calculated in mL/kg, as indicated in the prescribing information, is initiated at 0.15 mL/kg twice daily, with weekly escalation to a goal of 0.4 mL/kg twice daily. This is equivalent to a total dose of 3.4 mg/kg/day. Access to propranolol 4.28 mg/mL is via a single specialty pharmacy, purposefully imposed by the pharmaceutical company to verify dose calculations and provide support to caregivers. Before its approval, most pediatric dermatologists prescribed the lower concentration formulation of generic propranolol (4 mg/mL) to treat IH. We and other prescribers discovered dosing errors from pharmacy dispensing of the higher concentration formulation (8 mg/mL), with a potential risk of overdose in this infant population. We conducted an institutional review boardeapproved survey to identify prescriber experience with pharmacy dispensing errors and dose calculation errors associated with the generic formulations and propranolol 4.28 mg/mL. An online questionnaire was e-mailed to 531 physicians (members of Society for Pediatric Dermatology and physicians that treat IH). Fisher exact and Z tests were used to assess statistical associations.
The response rate was 41.4% (220/531). The majority (70.0%) of responders were pediatric dermatologists. Ninety percent reported prescribing generic propranolol and 58.6% had prescribed propranolol 4.28 mg/mL. At least 1 dispensing error associated with generic propranolol was reported by 18% of physicians (Fig 1) . Among prescribers of generic propranolol, 30% experienced $1 dose calculation error, either made personally or by an assistant. Only 11% of clinicians who prescribed propranolol 4.28 mg/mL reported a similar statistically significant error. A subset analysis of pediatric dermatologists yielded comparable results. Among prescribers with experience writing 10 to 100 prescriptions for generic propranolol and propranolol 4.28 mg/mL, 31% reported $1 dose calculation error with generic propranolol, compared to 10% with propranolol 4.28 mg/mL (Fig 2) . A dosing chart accompanies propranolol 4.28 mg/mL using mL/kg doses, which eliminates conversion from milligrams to milliliters, and could potentially explain the lower Medication errors cause $1 death every day and injure approximately 1.3 million people annually in the United States. 4 The risk of dispensing errors is increased for medications that are commercially available in different concentrations. Liquid medications prescribed for pediatric patients require additional computation for weight-based dosing and conversion, increasing the possibility of miscalculation. Our survey confirmed that both dispensing and dose calculation errors have occurred when prescribing generic propranolol for infants with IH. Dose calculation errors occurred less often with propranolol 4.28 mg/mL, and a single formulation distributed from 1 specialty pharmacy precludes dispensing errors. Pediatric dermatologists, who typically encounter and treat IH more frequently than other specialists, did not report fewer errors than other prescribers.
Although our study was not designed to evaluate the frequency of medication errors, it should help raise awareness of the risks and hopefully prevent associated adverse events. If the generic formulation of propranolol is prescribed, it is important to educate caregivers to check that the label is marked with the appropriate concentration. It may be helpful to incorporate electronic medical record orders or use an assistant to verify the calculation. (Table I) . ACD-specific QoL questionnaires are limited, and include the Fragrance Quality of Life Index and the Contact DermatitiseSpecific Questionnaire. 1, 2 An important gap in the current literature on QoL in ACD is the assessment of QoL over time, specifically before and after patch testing.
Anastasia
Our goal was to review previous studies assessing the impact of patch testing on QoL in patients recruited from patch test clinics. We conducted a search in the PubMed database, using the key words ''quality of life'' and ''contact dermatitis'' or ''patch testing.'' Only those studies that prospectively evaluated patient-reported QoL at baseline (before patch testing) and at follow-up (after patch testing) were included. Follow-up time varied from 6 weeks to 6 months (Table  II) . Studies assessing occupational contact dermatitis were excluded.
In all studies, patch testing led to improved QoL outcomes (Table II) . [3] [4] [5] In the study by Thomson et al, the DLQI score showed significant improvement 2 months after patch testing, but no significant changes were observed in the 36-item Short Form
